Xencor, Inc Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Xencor, Inc (XNCR) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $333.15 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $333.15M.
- 2026-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $370.21M.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $381.16M.
- 2025-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $358.49M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $333.15M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $370.21M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $381.16M 10-K · filed 2026-02-25 |
| 2025-09-30 | $358.49M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $358.98M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $381.02M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $408.97M 10-K · filed 2025-02-27 |
| 2024-09-30 | $435.04M 10-Q/A · filed 2025-02-24 |
| 2024-06-30 | $449.37M 10-Q/A · filed 2025-02-24 |
| 2024-03-31 | $460.37M 10-Q/A · filed 2025-02-24 |
| 2023-12-31 | $497.73M 10-K/A · filed 2025-02-24 |
| 2023-09-30 | $412.83M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $476.67M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $475.92M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $526.69M 10-K · filed 2023-02-27 |
| 2022-09-30 | $515.40M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $435.62M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $278.06M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $153.77M 10-K · filed 2022-02-24 |
| 2021-09-30 | $199.42M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $288.98M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $368.88M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $434.16M 10-K · filed 2021-02-24 |
| 2020-09-30 | $487.69M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $474.11M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $497.84M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $479.47M 10-K · filed 2020-02-25 |
| 2019-09-30 | $495.29M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $472.61M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $318.50M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $268.12M 10-K · filed 2019-02-26 |
| 2018-09-30 | $236.60M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $220.12M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $210.84M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $207.60M 10-K · filed 2018-02-28 |
| 2017-09-30 | $196.32M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $177.27M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $141.22M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $115.61M 10-Q · filed 2017-11-08 |
| 2016-09-30 | $89.52M 10-Q · filed 2016-11-02 |
| 2016-06-30 | $83.23M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $84.21M 10-Q · filed 2016-05-02 |
| 2015-12-31 | $83.84M 10-Q · filed 2016-11-02 |
| 2015-09-30 | $70.21M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $56.71M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $25.19M 10-Q · filed 2015-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |